Active Surveillance for Prostate Cancer: What to Expect and When to Act

Active surveillance (AS) is a management strategy for low-risk, localized prostate cancer that defers or avoids treatment through regular monitoring. It is not the same as ignoring the cancer — it is a structured approach that preserves the option for curative treatment while sparing men from the side effects of surgery or radiation unless and until they become necessary.

For appropriately selected men, active surveillance is oncologically equivalent to immediate treatment in terms of survival — while substantially better for quality of life. [^hamdy2016]

Who Is a Candidate for Active Surveillance

Not all prostate cancers are candidates for active surveillance. The generally accepted criteria for eligibility include:

Gleason score (Grade Group):

• Gleason 6 (Grade Group 1): ideal candidate
• Gleason 3+4=7 (Grade Group 2): increasingly accepted with careful monitoring
• Gleason 4+3=7 or higher: generally not appropriate for AS

PSA criteria:

• PSA below 10–15 ng/mL at diagnosis
• PSA density (PSA/prostate volume) below 0.15 ng/mL/mL preferred

Biopsy criteria:

• Fewer than 3 positive cores on standard 12-core biopsy
• Less than 50% involvement of any single core

Clinical stage:

• T1c or T2a (tumor not palpable, or involving less than half of one lobe)

Men with low-risk disease meeting these criteria have approximately a 1–2% prostate cancer-specific mortality risk at 10 years regardless of whether they choose immediate treatment or active surveillance — making AS a clinically rational choice. [^cooperberg2011]

Active Surveillance vs. Watchful Waiting

These terms are sometimes used interchangeably but represent different approaches:

Active surveillance has curative intent. It involves regular monitoring with the goal of identifying disease progression that warrants intervention. Men on AS are expected to pursue treatment if reclassification occurs.

Watchful waiting (or expectant management) is palliative in intent. It is typically chosen by older men or those with significant comorbidities who would not pursue curative treatment regardless of progression. The goal is symptom management rather than cure.

Most younger men with low-risk prostate cancer are counseled on active surveillance, not watchful waiting.

The Monitoring Protocol

Standard active surveillance protocols vary between institutions, but a typical regimen includes:

PSA testing: Every 3–6 months for the first 2 years, then every 6 months if stable. PSA velocity (rate of rise) and PSA doubling time are monitored alongside absolute values.

Digital rectal exam (DRE): Annually to monitor for palpable changes in the gland.

Repeat biopsy: The most important monitoring tool for detecting grade reclassification. Protocols differ:

• Traditional: systematic biopsy at 12–18 months, then every 2–4 years
• Modern: MRI-targeted biopsy, allowing more selective rebiopsy based on imaging findings

Multiparametric MRI (mpMRI): Increasingly used as part of AS protocols. mpMRI can identify suspicious regions for targeted biopsy, improving detection of clinically significant disease that initial systematic biopsy may have missed. [^tosoian2011]

What Triggers a Move to Treatment

Disease reclassification — evidence that the cancer has become higher-grade or higher-volume — is the primary trigger for transitioning from surveillance to active treatment. Specific triggers include:

• Grade reclassification to Gleason 4+3 or higher on repeat biopsy
• Significant increase in positive core number or core involvement
• PSA doubling time below 3 years (though this is institution-specific)
• New T3 clinical staging on imaging or exam
• Patient preference after counseling

Approximately 30–40% of men on active surveillance transition to treatment within 5–10 years. The majority of these transitions are due to grade reclassification rather than clinical progression or metastasis. [^klotz2010]

Long-Term Outcomes

The landmark ProtecT trial randomized 1,643 men with localized prostate cancer to active monitoring, radical prostatectomy, or radiotherapy and followed them for 10 years. [^hamdy2016] Key findings:

• Prostate cancer-specific mortality was low in all three groups (approximately 1%)
• No significant difference in survival between active monitoring and immediate treatment
• Metastatic events were more common in the monitoring group (6.3% vs. 2.4% for surgery, 3.0% for radiation) — but most did not result in prostate cancer death
• Treatment side effects (incontinence, erectile dysfunction) were substantially higher in the surgery and radiation groups

The Johns Hopkins active surveillance cohort, one of the longest-running, showed a 15-year prostate cancer-specific survival rate of 99% in carefully selected men. [^carter2007]

Treatment Side Effects Active Surveillance Avoids

This is the core rationale for AS. Both surgery and radiation carry significant risks of permanent side effects:

Radical prostatectomy:

• Urinary incontinence: 15–30% at one year, some improvement over time
• Erectile dysfunction: 40–70% at one year, recovery varies
• Retrograde ejaculation: near-universal

Radiation therapy:

• Bowel and urinary irritation during and after treatment
• Erectile dysfunction: 20–50% at five years
• Secondary radiation effects (rare but possible)

Men on active surveillance avoid these until (and unless) treatment becomes necessary. For men who remain on surveillance long-term without reclassification, many never experience these side effects. [^sanda2008]

Psychological Considerations

Living with an untreated cancer diagnosis creates anxiety for many men, and this is a legitimate consideration in AS decisions. Research shows that anxiety levels in AS are highest in the first year and decline to near-normal levels in men who remain on protocol. [^bokhorst2016]

Factors that improve psychological adaptation to AS:

• Clear understanding of the low-risk biology of their specific cancer
• Confidence in the monitoring protocol and their medical team
• Involvement of partners or family in counseling discussions
• Connection with AS peer support groups or patient communities

Men who find the psychological burden of AS intolerable should not be pressured to continue — quality of life includes mental health, and choosing treatment for psychological reasons is a legitimate decision.

Limitations and Uncertainties

Active surveillance has well-documented limitations:

Sampling error: Standard biopsies sample approximately 1–2% of prostate tissue. Higher-grade disease in unsampled regions can be missed at initial diagnosis. This is the primary reason mpMRI has become important in AS protocols — it helps identify regions that warrant targeted sampling.

Gleason upgrading rate: 20–40% of men diagnosed with Gleason 6 on standard biopsy are found to have higher-grade disease on subsequent mpMRI-targeted or radical prostatectomy specimens. This does not mean AS failed — it means the initial biopsy was incomplete — but it underscores the importance of rigorous monitoring.

Long-term data limitations: Most AS cohorts have 10–15 year follow-up. Data beyond 20 years are limited, which creates some uncertainty for younger men (under 55) diagnosed with low-risk disease.

Bottom Line

Active surveillance is a guideline-supported, evidence-backed approach for men with low-risk localized prostate cancer. It delivers survival outcomes equivalent to immediate treatment while preserving quality of life until progression is documented. Successful AS requires commitment to a structured monitoring program, a skilled medical team experienced with the approach, and psychological readiness to live with a monitored diagnosis. For appropriately selected men who understand its rationale and requirements, it is often the best initial management choice.